InvestorsHub Logo
Followers 840
Posts 120475
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 1040

Wednesday, 02/16/2022 10:32:17 AM

Wednesday, February 16, 2022 10:32:17 AM

Post# of 1168
Mavacamten phase-3 succeeds in patients with obstructive HCM eligible for septal reduction therapy:

https://www.businesswire.com/news/home/20220215005925/en

Note: The above is a narrower indication than the one BMY is seeking in the existing NDA that has a 4/28/22 PDUFA date.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News